ProCE Banner Activity

NASH Heterogeneity: Lessons From the Past and Future Directions

Clinical Thought
Read my take on NASH heterogeneity and its implications for treatment.

Released: September 29, 2022

Expiration: September 28, 2023

No longer available for credit.

Share

Faculty

Brent A. Neuschwander-Tetri

Brent A. Neuschwander-Tetri, MD

Professor of Internal Medicine
Saint Louis University Liver Center
Division of Gastroenterology and Hepatology
Saint Louis University School of Medicine
St. Louis, Missouri

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Novo Nordisk Inc

Faculty Disclosure

Primary Author

Brent A. Neuschwander-Tetri, MD

Professor of Internal Medicine
Saint Louis University Liver Center
Division of Gastroenterology and Hepatology
Saint Louis University School of Medicine
St. Louis, Missouri

Brent A. Neuschwander-Tetri, MD: consultant/advisor/speaker: 89Bio, Akero, Alimentiv, Allergan, Allysta, Alnylam, Amgen, Arrowhead, Axcella, Boehringer Ingelheim, Bristol Myers Squibb, Coherus, Cymabay, Durect, Enanta, Fortress, Genfit, Gilead, Glympse, Hepeon, HighTide, HistolIndex, Innovo, Intercept, Ionis, LG Chem, Lipocine, Madrigal, MedImmune, Merck, Mirum, NGM, NovoNordisk, Novus Therapeutics, pH-Pharma, Sagimet, Target RWE, Theratechnologies; stock options: HepGene; researcher (paid to institution): Allergan, Bristol Myers Squibb, Celgene, Cirius, Enanta, Genfit, Gilead, HighTide, Intercept, Inventiva, Madrigal, NGM.